

PRODUCT INFORMATION

ACD22-VCMMAE, DCDT2980S, FCU2803, RG-7593, **Common Name**

RO5541072-000, Unconjugated mAb

Synonyms CD22;SIGLEC2;BL-CAM;SIGLEC-2;Siglec2;SIGLEC2FLJ22814

Conjugate Unconjugated **Applications** ELISA; Flow Cyt

Recommended

Dilutions

Background

ELISA 1:5000-10000; Flow Cyt 1:100

Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% Formulation & trehalose is added as protectants before lyophilization. Reconstitution Please see Certificate of Analysis for specific instructions

of reconstitution.

Host Species Humanized

IgG type lgG1 Reactivity Human **Target** CD22 **Uniprot ID** P20273

Description Anti-CD22 (pinatuzumab biosimilar) mAb

Delivery In Stock

Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a

Storage & Shipping month, aliquot and store at -80°C (Avoid repeated


freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. Our unconjugated biosimilar monoclonal antibodies (mAbs) are based on the sequences outlined in relevant patents or scientific publications. These antibodies are in their native, unconjugated form, meaning they do not contain any payload or therapeutic agent attached. They are designed for use in research and development, and their performance has been tested as standalone molecules through comprehensive QC tests.

Usage Research use only

> All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

DIMA Disclaimer



Email: info@dimabio.com Website: www.dimabio.com





Anti-CD22 (pinatuzumab vedotin biosimilar) mAb ELISA




Figure 1. ELISA plate pre-coated by 2 μ g/ml (100 μ L/well) Human CD22, hFc-His tagged protein (PME100005) can bind Anti-CD22 Neutralizing antibody in a linear range of 3.2-400 ng/ml. In order to specifically detect BME100029, mouse anti-human Fab-specific antibody was used as detection antibody.




Figure 2. HEK293 cell line transfected with irrelevant protein **(B)** and human CD22 **(A)** were surface stained with Anti-CD22 mAb 1 μ g/ml (pinatuzumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.

Email: info@dimabio.com Website: www.dimabio.com

